Evidence map›Paper›PMID 41423269›Full record

ArticleJournal for immunotherapy of cancer2025

Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).

Sam Sater, Carlo B Bifulco, Jaime Rodriguez-Canales, Joe Yeong, Guray Akturk, Michael Angelo, Carmen Ballesteros-Merino, Peter Bankhead, Subham Basu, Jorge M Blando and 50 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Emerging technologies in the spatial proteomics landscape.Analytical and bioanalytical chemistry · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

60 authors.

Sam Sater *HAS Consulting, Miami, Florida, USA.
Carlo B Bifulco *Providence Molecular Genomics Laboratory, Portland, Oregon, USA.
Jaime Rodriguez-Canales *Daiichi Sankyo Inc, Basking Ridge, New Jersey, USA.
Joe Yeong *Department of Anatomical Pathology, Singapore General Hospital, Singapore.
Guray AkturkMerck & Co Inc, Kenilworth, New Jersey, USA.
Michael AngeloDepartment of Pathology, Stanford University, Stanford, California, USA.
Carmen Ballesteros-MerinoBristol Myers Squibb, San Diego, California, USA.
Peter BankheadEdinburgh Pathology, Centre for Genomic & Experimental Medicine and CRUK Scotland Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
Subham BasuNavinci Diagnostics, Uppsala, Sweden.
Jorge M BlandoAstraZeneca, Gaithersburg, Maryland, USA.
Saska BrajkovicLunaphore Technologies, Tolochenaz, Switzerland.
Marco CassanoLunaphore Technologies, Tolochenaz, Switzerland.
Benjamin J ChenBristol Myers Squibb, Cambridge, Massachusetts, USA.ORCID http://orcid.org/0000-0002-2422-2551
Ahmet F CoskunDepartment of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Tricia R CottrellDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
Carlos E De AndreaInstituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Robin H EdwardsRobin H. Edwards Consulting, LLC, Newtown, Pennsylvania, USA.
Colt EgelstonDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, California, USA.ORCID http://orcid.org/0000-0001-8440-1271
Logan L EngleDepartment of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID http://orcid.org/0000-0002-6375-9060
Marc S ErnstoffDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-8132-7069
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0001-7805-8059
Michael FeldmanDepartment of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Bernard A FoxLaboratory of Molecular and Tumor Immunology, Earle A Chiles Research Institute, Portland, Oregon, USA.ORCID http://orcid.org/0000-0002-4452-5947
Jerome GalonINSERM, Equipe Labellisée Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris, France.
Robyn GartrellDepartment of Oncology, Division of Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sacha GnjaticDepartment of Immunology and Immunotherapy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Benjamin F GreenThe Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
James L GulleyCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-6569-2912
Anne HellebustIndica Labs, Albuquerque, New Mexico, USA.
Stephen HewittLaboratory of Pathology, National Institutes of Health, Bethesda, Maryland, USA.
Travis J HollmannBristol Myers Squibb, Princeton, New Jersey, USA.
Lucas A HornCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0001-6011-2061
William J HowatAbcam, Cambridge, England, UK.
Clifford C HoytQuanterix Corp, Billerica, Massachusetts, USA.
Shawn M JensenLaboratory of Molecular and Tumor Immunology, Earle A Chiles Research Institute, Portland, Oregon, USA.
Arutha KulasingheFrazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Wiem LassouedCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0009-0004-5742-6982
Steven LottBruker Spatial Biology, San Jose, California, USA.
James MansfieldStandard BioTools, Markhan, ON, Canada.
Sebastian MarwitzHistology, Research Center Borstel - Leibniz Lung Center, Borstel, Germany.ORCID http://orcid.org/0000-0003-4920-5552
George NettoUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
David B PageEarle A Chiles Research Institute, Portland, Oregon, USA.ORCID http://orcid.org/0000-0001-9264-4628
Edwin ParraDepartment of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
David L RimmDepartments of Pathology and Medicine (Oncology), Yale School of Medicine, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0001-5820-4397
Scott J RodigBrigham and Women's Hospital, Boston, Massachusetts, USA.
Roberto SalgadoDepartment of Pathology, GasthuisZusters Antwerpen, Antwerp, Belgium.
Denis SchapiroInstitute for Computational Biomedicine, Heidelberg University, Heidelberg, Germany.
Kurt A SchalperDepartments of Pathology and Medicine (Oncology), Yale School of Medicine, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0001-5692-4833
Joel C SunshineDivision of Dermatopathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID http://orcid.org/0000-0001-9987-6712
Michael J SuraceAstraZeneca, Gaithersburg, Maryland, USA.
Alexander S SzalayDepartment of Astronomy and Physics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Magdalena ThurinCancer Diagnosis Program, National Cancer Institute, Bethesda, Maryland, USA.
Jose C VillasboasDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Keith WhartonUltivue, Inc, Cambridge, Massachusetts, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jennifer H YearleyMerck, Rahway, New Jersey, USA.
Yinyin YuanDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Geroge ZakiBiomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
James ZiaiGenentech, South San Francisco, California, USA.
Janis M TaubeDivision of Dermatopathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA jtaube1@jh.edu.ORCID http://orcid.org/0000-0002-8273-4395

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiplex immunofluorescence and immunohistochemistry (mIF/IHC) are increasingly employed antibody-based technologies that use tissue sparingly and facilitate the detection of co-localized or neighboring biomarkers. Specifically, these platforms enable spatial analyses of the tumor microenvironment as well as extended applications, for example, describing normal tissue anatomy, autoimmunity, infectious diseases, etc. mIF/IHC has greatly enhanced biomarker discovery efforts, and a growing number of studies suggest superiority to traditional IHC. Standardization of staining approaches, reporting of image analysis strategies and resultant data is critical for facilitating cross-study comparisons, validation, deployment, and generalization of findings. To address this challenge, The Society for Immunotherapy of Cancer (SITC) previously published two articles providing best practice guidelines for mIF/IHC staining, image analysis, and data sharing. Here, SITC convened stakeholders to develop the third article in the series, a consensus checklist for scientific reporting of mIF/IHC data to support and complement the best practice guidelines. The checklist includes critical components of mIF/IHC applications to be defined within publications such as detailed descriptions of analytical validation; image acquisition, selection, and registration methods; and cell clustering and spatial analysis strategies, amongst others. Such information will help with data reproducibility and comparison across studies towards future drug and assay development.

Indexed as

Biomarkers, TumorFluorescent Antibody TechniqueImmunohistochemistryImmunotherapyNeoplasmsHumansTumor MicroenvironmentBiomarkers, TumorBiomarkerImmunotherapyPathologyTumor microenvironment - TME

Identifiers

PMID41423269
PMCPMC12718562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.